- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
NORDIC CAPITAL / LEO FOUNDATION / LEO PHARMA
M.10238
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
1.1. Nordic Capital Fund X intends to acquire a joint-controlling stake in LEO Pharma A/S (“LEO Pharma”). LEO Pharma is currently controlled and wholly held by LEO Foundation.
2.2. Nordic Capital is a group of private equity funds focusing on investments primarily in the Nordic region of Europe and selected Northern European sectors. Nordic Capital invests across a wide range of industries but has a particular focus on healthcare, technology and payments, financial services, industrial and business services and consumer products.
3.3. LEO Pharma is headquartered in Denmark and develops, manufactures and markets pharmaceutical products to be used predominantly for treatment of dermatological and thrombotic diseases. LEO Pharma Group’s product portfolio consists of branded and generic products for the treatment of skin diseases including psoriasis, atopic eczema and acne. In addition, the portfolio includes prophylactic measures and treatments for thrombosis (blood clots), in particular for the treatment of deep vein thrombosis and pulmonary embolism. LEO Pharma Group has commercial operations in more than 130 countries across Europe, Asia Pacific, Americas and Africa and manufacturing sites in Denmark, France, Ireland and Italy.
4.4. LEO Pharma is wholly-owned by LEO Foundation. LEO Foundation is a private foundation established under Danish law which does not control any other operating undertakings and which is itself not controlled by any other entities. LEO Foundation’s financial assets are held in LEO Holding, where the investments activities of the LEO Foundation are carried out.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.